Makoto Sasaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Makoto Sasaki has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Yutaka Tsukune
Department of Hematology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, 113-8421, Japan
4 shared publicationsKoichi Sugimoto
Juntendo University
3 shared publicationsNorio Komatsu
Department of Hematology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, 113-8421, Japan
3 shared publicationsAtsushi Isoda
Department of Hematology, National Hospital Organization Shibukawa Medical Center, Shibukawa, Gunma, 377-0280, Japan
2 shared publicationsAzuchi Masuda
Juntendo University School of Medicine
2 shared publicationsHiroki Sugimori
Department of Preventive Medicine, Daito Bunka University, Graduate School of Sports and Health Science, Higashi-Matsuyama, Saitama, 355-8501, Japan
2 shared publications
Latest Publications
- Open Access
Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma
Reactivation of hepatitis B virus (HBV) is a well-known complication in patients with hematological malignancies during or after cytotoxic chemotherapy. If the initiation of antiviral therapy is delayed in patients with HBV reactivation, these patients can develop severe hepatitis and may die of fulminant hepatitis. The preventive strategy for HBV reactivation in patients with malignant lymphoma has already been established based on some prospective studies. As there was an increased number of novel agents being approved for the treatment of multiple myeloma (MM), the number of reported cases of HBV reactivation among MM patients has gradually increased. We conducted a Japanese nationwide retrospective study and revealed that HBV reactivation in MM patients is not rare and that autologous stem cell transplantation is a significant risk factor. In this study, around 20% of all patients with HBV reactivation developed HBV reactivation after 2 years from the initiation of therapy, unlike malignant lymphoma. This might be due to the fact that almost all of the patients received chemotherapy for a long duration. Therefore, a new strategy for the prevention of HBV reactivation in MM patients is required.
Open AccessReactivation of Hepatitis B Virus in Patients with Multiple Myeloma
Reactivation of hepatitis B virus (HBV) is a well-known complication in patients with hematological malignancies during or after cytotoxic chemotherapy. If the initiation of antiviral therapy is delayed in patients with HBV reactivation, these patients can develop severe hepatitis and may die of fulminant hepatitis. The preventive strategy for HBV reactivation in patients with malignant lymphoma has already been established based on some prospective studies. As there was an increased number of novel agents being approved for the treatment of multiple myeloma (MM), the number of reported cases of HBV reactivation among MM patients has gradually increased. We conducted a Japanese nationwide retrospective study and revealed that HBV reactivation in MM patients is not rare and that autologous stem cell transplantation is a significant risk factor. In this study, around 20% of all patients with HBV reactivation developed HBV reactivation after 2 years from the initiation of therapy, unlike malignant lymphoma. This might be due to the fact that almost all of the patients received chemotherapy for a long duration. Therefore, a new strategy for the prevention of HBV reactivation in MM patients is required.
- Open Access
- 23 November 2017
- Published by Springer Nature in Blood Cancer Journal
- Vol. 7 (12) , 1-6
Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan
- 23 November 2017
- Published by Springer Nature in Blood Cancer Journal
- Vol. 7 (12) , 1-6
Open AccessIncidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan
- 30 June 2016
- Published by Springer Nature in Annals of Hematology
- Vol. 95 (9) , 1465-1472
Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents’ era
There are some reports regarding hepatitis B virus (HBV) reactivation in patients with myeloma who are HBV carriers or who have had a resolved HBV infection, and there is no standard prophylaxis strategy for these patients. We performed a retrospective multicenter study to determine the incidence and characteristics of HBV reactivation in patients with multiple myeloma. We identified 641 patients with multiple myeloma who had been treated using novel agents and/or autologous stem cell transplantation with high-dose chemotherapy between January 2006 and June 2014 at nine Japanese hospitals. The patients’ characteristics, laboratory data, and clinical courses were retrieved and statistically analyzed. During a median follow-up of 101 weeks, one of eight (12.5 %) HBV carriers developed hepatitis and 9 of 99 (9.1 %) patients with resolved HBV infection experienced HBV reactivation; the cumulative incidences of HBV reactivation at 2 years (104 weeks) and 5 years (260 weeks) were 8 and 14 %, respectively. The nine cases of reactivation after resolved HBV infection had received entecavir as preemptive therapy or were carefully observed by monitoring their HBV DNA levels, and none of these cases developed hepatitis. Among patients with multiple myeloma, HBV reactivation was not rare. Therefore, long-term monitoring of HBV DNA levels is needed to prevent hepatitis that is related to HBV reactivation in these patients.
- 30 June 2016
- Published by Springer Nature in Annals of Hematology
- Vol. 95 (9) , 1465-1472
Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents’ era
There are some reports regarding hepatitis B virus (HBV) reactivation in patients with myeloma who are HBV carriers or who have had a resolved HBV infection, and there is no standard prophylaxis strategy for these patients. We performed a retrospective multicenter study to determine the incidence and characteristics of HBV reactivation in patients with multiple myeloma. We identified 641 patients with multiple myeloma who had been treated using novel agents and/or autologous stem cell transplantation with high-dose chemotherapy between January 2006 and June 2014 at nine Japanese hospitals. The patients’ characteristics, laboratory data, and clinical courses were retrieved and statistically analyzed. During a median follow-up of 101 weeks, one of eight (12.5 %) HBV carriers developed hepatitis and 9 of 99 (9.1 %) patients with resolved HBV infection experienced HBV reactivation; the cumulative incidences of HBV reactivation at 2 years (104 weeks) and 5 years (260 weeks) were 8 and 14 %, respectively. The nine cases of reactivation after resolved HBV infection had received entecavir as preemptive therapy or were carefully observed by monitoring their HBV DNA levels, and none of these cases developed hepatitis. Among patients with multiple myeloma, HBV reactivation was not rare. Therefore, long-term monitoring of HBV DNA levels is needed to prevent hepatitis that is related to HBV reactivation in these patients.
- 23 October 2012
- Published by Springer Nature
- p. 21-27
Central Nervous System Recurrence in the Primary Mediastinal Large B-Cell Lymphoma: Treatment
- 23 October 2012
- Published by Springer Nature
- p. 21-27
Central Nervous System Recurrence in the Primary Mediastinal Large B-Cell Lymphoma: Treatment
- Open Access
- 10 July 2012
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 6 (1) , 193
Malignant lymphoma with diffuse cardiac involvement detected by multiple imaging examinations: a case report
In malignant lymphoma, cardiac involvement, which usually forms pathologically focal and firm nodules in the cardiac walls, is considered to be a late manifestation of the disease. We describe the case of a 71-year-old Asian Japanese woman whose first presentation of lymphoma was congestive heart failure. Multiple imaging examinations and laboratory findings led to a presumed diagnosis of a malignant lymphoma. A tissue diagnosis of the mediastinal mass could not be performed due to our patient’s generally poor condition. Our patient received corticosteroid therapy, but died 42 days after her admission. An autopsy revealed lymphoid cells encircling her ventricular wall and infiltrating her endocardium. A histological examination confirmed the diagnosis of diffuse large B-cell lymphoma. Imaging examinations such as echocardiography, computed tomography with three-dimensional reconstruction, and gallium-67-citrate scintigraphy could clearly detect the diffuse cardiac involvement antemortem. A combination of these imaging techniques could provide a working diagnosis and allow empirical initiation of treatment in patients with poor general condition.
- 10 July 2012
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 6 (1) , 193
Open AccessMalignant lymphoma with diffuse cardiac involvement detected by multiple imaging examinations: a case report
In malignant lymphoma, cardiac involvement, which usually forms pathologically focal and firm nodules in the cardiac walls, is considered to be a late manifestation of the disease. We describe the case of a 71-year-old Asian Japanese woman whose first presentation of lymphoma was congestive heart failure. Multiple imaging examinations and laboratory findings led to a presumed diagnosis of a malignant lymphoma. A tissue diagnosis of the mediastinal mass could not be performed due to our patient’s generally poor condition. Our patient received corticosteroid therapy, but died 42 days after her admission. An autopsy revealed lymphoid cells encircling her ventricular wall and infiltrating her endocardium. A histological examination confirmed the diagnosis of diffuse large B-cell lymphoma. Imaging examinations such as echocardiography, computed tomography with three-dimensional reconstruction, and gallium-67-citrate scintigraphy could clearly detect the diffuse cardiac involvement antemortem. A combination of these imaging techniques could provide a working diagnosis and allow empirical initiation of treatment in patients with poor general condition.
- 13 February 2010
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 99 (2) , 295-296
Early CNS relapse in a good-risk primary mediastinal large B-cell lymphoma after combined chemo- and radio-therapy
- 13 February 2010
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 99 (2) , 295-296
Early CNS relapse in a good-risk primary mediastinal large B-cell lymphoma after combined chemo- and radio-therapy
- 1 April 2009
- Published by S. Karger AG in Acta Haematologica
- Vol. 121 (1) , 63-66
Establishment of a Hairy Cell Leukemia Variant Cell Line, HCLv-07
- 1 April 2009
- Published by S. Karger AG in Acta Haematologica
- Vol. 121 (1) , 63-66
Establishment of a Hairy Cell Leukemia Variant Cell Line, HCLv-07